CADScor®System

An innovative first-line diagnostic aid to rule out  significant Coronary Artery Disease

CADScor®System

A new first line rule-out device for significant CAD

CADScor®System

A new first line rule-out device for significant CAD

Acarix at Naventus Health Care Summit 2022 

Helen Ljungdahl Round, President and CEO of Acarix AB (publ), did present at the Naventus Health Care Summit in Stockholm on May 10, 2022. 

 

 

 

CAD-score in just 10 minutes

See how easy it is getting your CAD-score in the clinic – in just 10 minutes.

 

 

 

 

A simple test to put a patient's mind at rest

The CADScor®System is an innovative, ultrasensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant CAD at the very first stage of the diagnostic pathway. The user-friendly test records and analyses the heart sounds of the patient and can be conducted by all trained healthcare professionals.

 

 

 

 

An easy solution to bring down costs, risk and stress

Founded image placeholder
Non-invasive, point-of-care-test reducing waiting time and stress for patients
Founded image placeholder
User-friendly, accurate and reliable rule-out diagnostic aid to be used prior to other testing
Founded image placeholder
Cost-effective and safe diagnostic aid displaying immediate results

A brief introduction to how the CADScor®System works

Based on acoustic technology, the CADScor®System records the heart sounds of the resting patient to analyse the myocardial movement and blood flow in the coronary arteries. The recording detects heart sound abnormalities, such as coronary murmurs correlated to coronary stenosis and stiffness. In less than ten minutes, the result is shown as a calculated CAD-score from 0-99, categorizing patients into three risk groups.

“The CADScor®System gives you peace of mind in just 10 minutes”

For investors

Acarix is a medical technology company marketing the CADScor®System, currently available in Sweden, Denmark and Germany. The CADScor®System is developed from pioneering research on phonocardiography, providing an innovative, non-invasive and ultra-sensitive analytical diagnostic aid for immediate rule-out. The cost-effective and simple test has the potential to reduce the waiting time and stress for patients experiencing symptoms of CAD. Since 2016, Acarix is listed on Nasdaq First North Growth Market.

Updates